home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.410 -0.070 (-2.01%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Via Benzinga

Topics Artificial Intelligence ETFs

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma ↗

July 25, 2025

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Via Benzinga

3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities ↗

July 23, 2025

Via The Motley Fool

Topics Artificial Intelligence

Biocomputers: The Future of Computing is Alive

July 22, 2025

In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 08, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism

July 22, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes...

Via MarketMinute

Topics Artificial Intelligence

Top 2 Health Care Stocks You May Want To Dump This Quarter ↗

July 22, 2025

Via Benzinga

History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)

July 21, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and...

Via MarketMinute

Topics Artificial Intelligence

Is Recursion Pharmaceuticals Gaining or Losing Market Support? ↗

July 21, 2025

Via Benzinga

Why Is Recursion Pharma Stock Surging On Monday? ↗

July 21, 2025

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

Via Benzinga

Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗

July 21, 2025

Via Benzinga

Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch. ↗

July 12, 2025

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering Intellectual Property

10 Under-the-Radar Tech Stocks With Incredible Growth Potential ↗

July 09, 2025

Just because it's not a household name doesn't mean it's not a magnificent investment.

Via The Motley Fool

Topics Artificial Intelligence

Here's Why Shares in Recursion Pharmaceuticals Surged Today ↗

July 08, 2025

Via The Motley Fool

Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday ↗

July 08, 2025

Via Benzinga

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? ↗

July 08, 2025

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.

Via Benzinga

The Hottest 10 Artificial Intelligence (AI) Stocks on the Market ↗

July 08, 2025

This group of companies reflects most of the industry's past, present, and future.

Via The Motley Fool

Topics Artificial Intelligence

Doctors Are Being Outpaced by AI-Powered Algorithms — Here’s What It Means for Investors

July 07, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:MSFT),(NASDAQ:ASTH),(NASDAQ:RXRX),(NASDAQ:MDAI) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Fraud

Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...' ↗

July 07, 2025

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Via Benzinga

Topics Artificial Intelligence

What Analysts Are Saying About Recursion Pharmaceuticals Stock ↗

July 03, 2025

Via Benzinga

Is the Market Bullish or Bearish on Recursion Pharmaceuticals? ↗

June 26, 2025

Via Benzinga

Capital Flows Shift From Research Labs to Pharmacy Counters-A Watershed Moment for AI Health

June 17, 2025

Issued on behalf of Avant Technologies Inc. Vancouver, BC – June 17, 2025 – USA News Commentary – Momentum continues to build behind AI in healthcare, as capital finds its way to technologies capable...

Via FinancialNewsMedia

Topics Artificial Intelligence

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts ↗

June 16, 2025

Via Benzinga

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? ↗

June 16, 2025

Via The Motley Fool

Topics Animal Testing Artificial Intelligence Intellectual Property

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday ↗

June 10, 2025

Via The Motley Fool

Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? ↗

June 10, 2025

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.

Via Benzinga

Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday ↗

June 10, 2025

Via Benzinga

Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead ↗

June 10, 2025

The company now expects its projected cash runway to extend into the fourth quarter of 2027.

Via Stocktwits

Topics Artificial Intelligence Workforce

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗

June 08, 2025

Via Benzinga

Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT ↗

June 06, 2025

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict...

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com